Skip to main content
. 2021 Apr 19;5(8):2120–2128. doi: 10.1182/bloodadvances.2020003988

Table 2.

Transplant characteristics and incidence of TA-TMA

Overall Preprophylaxis implementation Postprophylaxis implementation
Overall, n (%) One-year cumulative incidence of TA-TMA, % (95% CI) P Overall, n (%) One-year cumulative incidence of TA-TMA, % (95% CI) P Overall, n (%) One-year cumulative incidence of TA-TMA, % (95% CI) P
Conditioning .17 .29 .02
 TBI-MAC 43 (17) 12.2 (2.2-22.2) 32 (20) 9.8 (0.3-19.3) 11 (11) 19.2 (0-43.1)
 Non TBI-MAC* 171 (66) 5.7 (2-9.4) 101 (63) 8.5 (2.8-14.2) 70 (73) 1.6 (0-4.7)
 RIC or NMA 43 (17) 2.4 (0-7.1) 28 (17) 0 15 (16) 7.1 (0-20.6)
Stem cell source .40 .47 .86
 Bone marrow 88 (34) 4.7 (0.2-9.2) 46 (29) 4.7 (0-11) 42 (44) 4.9 (0-11.6)
 PBSCs 153 (60) 7.8 (3.3-12.3) 106 (66) 9.1 (3.4-14.8) 47 (49) 4.6 (0-10.9)
 Cord 16 (6) 0 9 (5) 0 7 (7) 0
Donor type .13 .02 .82
 MRD 60 (23) 5 (0-10.5) 32 (20) 3.1 (0-9.1) 28 (29) 7.1 (0-16.7)
 MMRD (9/10) 3 (1) 0 3 (2) 0 0
 Haploidentical 58 (23) 14.2 (4.4-24) 31 (19) 22.1 (6.4-37.8) 27 (28) 3.7 (0-10.7)
 MUD (10/10) 92 (36) 3.4 (0-7.1) 58 (36) 3.5 (0-8.4) 34 (36) 3.2 (0-9.5)
 MMUD (≤9/10) 44 (17) 4.9 (0-11.6) 37 (23) 5.8 (0-13.6) 7 (7) 0
HLA-mismatch (<10/10) .08 .04 .79
 No 152 (59) 4.1 (1-7.2) 90 (56) 3.4 (0-7.1) 62 (64) 5 (0-10.5)
 Yes 105 (41) 9.9 (3.8-16) 71 (44) 12.7 (4.5-20.9) 34 (36) 2.9 (0-8.6)
Minor ABO mismatch .98 .58 .27
 No 189 (74) 6.3 (2.8-9.8) 115 (71) 6.5 (1.8-11.2) 74 (77) 5.9 (0.4-11.4)
 Yes 68 (26) 6.3 (0.4-12.2) 46 (29) 9.1 (0.7-17.5) 22 (23) 0
Pre-HSCT CNI exposure .003 .02 .07
 No 238 (93) 5 (2.1-7.9) 147 (91) 5.8 (1.9-9.7) 91 (95) 3.6 (0-7.5)
 Yes 19 (7) 22.4 (3-41.8) 14 (9) 22.6 (0.1-45.1) 5 (5) 20 (0-55)

MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor.

*

Conditioning regimens for patients with Fanconi anemia were considered MAC.

One patient received PBSC + marrow.

Three patients received cord + marrow.